Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208907> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4387208907 endingPage "S64" @default.
- W4387208907 startingPage "S63" @default.
- W4387208907 abstract "Benefit of radiotherapy (RT) after chemotherapy (CT) of diffuse large B-cell lymphoma (DLBCL) remains controversial. It is unknown whether improved progression-free survival (PFS) by RT translate into an overall survival (OS) benefit. To address this question, our research comprehensively evaluated the risk-benefit assessment of RT in DLBCL through an in-depth examination of previously reported data from randomized controlled trials (RCTs) and retrospective comparative studies.After screening and quality control, this study included 7 randomized controlled trials and 52 retrospective studies of combined-modality therapy (CMT) versus CT alone. The correlation between PFS and OS was evaluated using the Pearson linear correlation coefficient at trial- and study arm-level. A risk-benefit assessment to describe the OS benefit of RT was performed in meta-analyses of pooled HROS with PFS patterns.In RCTs, strong correlations were found between HRPFS and HROS at trial-level (r = 0.876), and PFS and OS at treatment arm-level, regardless of treatments (r = 0.945-0.964 for all, CMT or CT). In retrospective studies, similar correlations between HRPFS and HROS (r = 0.639-0.650), and PFS and OS rates (r = 0.882-0.910) were observed, independent of treatments or rituximab. Adding RT into rituximab-based CT increased the average PFS rate from 63.6 ± 18.9% to 81.5 ± 10.6% (P<0.001), with differential OS benefits of RT between studies. Patients can be stratified into four PFS patterns (>80%, >60-80%, >40-60%, and ≤40%); absolute gain in OS from RT ranged from ≤5% at PFS >80% to ∼21% at PFS ≤40%, with pooled-HROS from 0.70 (95% CI, 0.51-0.97) to 0.48 (95% CI, 0.36-0.63) after rituximab-based CT. Linear analysis revealed an OS advantage of CMT over CT alone in a PFS-dependent manner.We demonstrate a varied OS benefit profile of RT upon different PFS patterns, and provide valuable evidence for making treatment decisions and designing clinical trials. Future strategies to select the use of RT will need careful tailoring in clinical practice or within RCT to optimize outcome." @default.
- W4387208907 created "2023-09-30" @default.
- W4387208907 creator A5014538923 @default.
- W4387208907 creator A5018742393 @default.
- W4387208907 creator A5037677450 @default.
- W4387208907 creator A5046591981 @default.
- W4387208907 creator A5048995364 @default.
- W4387208907 creator A5049217765 @default.
- W4387208907 creator A5080769460 @default.
- W4387208907 creator A5080793835 @default.
- W4387208907 date "2023-10-01" @default.
- W4387208907 modified "2023-10-16" @default.
- W4387208907 title "Association of Overall Survival Benefit Profile of Radiotherapy with Progression-Free Survival after Chemotherapy for Diffuse Large B-Cell Lymphoma" @default.
- W4387208907 doi "https://doi.org/10.1016/j.ijrobp.2023.06.364" @default.
- W4387208907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784543" @default.
- W4387208907 hasPublicationYear "2023" @default.
- W4387208907 type Work @default.
- W4387208907 citedByCount "0" @default.
- W4387208907 crossrefType "journal-article" @default.
- W4387208907 hasAuthorship W4387208907A5014538923 @default.
- W4387208907 hasAuthorship W4387208907A5018742393 @default.
- W4387208907 hasAuthorship W4387208907A5037677450 @default.
- W4387208907 hasAuthorship W4387208907A5046591981 @default.
- W4387208907 hasAuthorship W4387208907A5048995364 @default.
- W4387208907 hasAuthorship W4387208907A5049217765 @default.
- W4387208907 hasAuthorship W4387208907A5080769460 @default.
- W4387208907 hasAuthorship W4387208907A5080793835 @default.
- W4387208907 hasConcept C126322002 @default.
- W4387208907 hasConcept C143998085 @default.
- W4387208907 hasConcept C167135981 @default.
- W4387208907 hasConcept C168563851 @default.
- W4387208907 hasConcept C2776694085 @default.
- W4387208907 hasConcept C2778559949 @default.
- W4387208907 hasConcept C2779338263 @default.
- W4387208907 hasConcept C2780653079 @default.
- W4387208907 hasConcept C2780739268 @default.
- W4387208907 hasConcept C509974204 @default.
- W4387208907 hasConcept C71924100 @default.
- W4387208907 hasConceptScore W4387208907C126322002 @default.
- W4387208907 hasConceptScore W4387208907C143998085 @default.
- W4387208907 hasConceptScore W4387208907C167135981 @default.
- W4387208907 hasConceptScore W4387208907C168563851 @default.
- W4387208907 hasConceptScore W4387208907C2776694085 @default.
- W4387208907 hasConceptScore W4387208907C2778559949 @default.
- W4387208907 hasConceptScore W4387208907C2779338263 @default.
- W4387208907 hasConceptScore W4387208907C2780653079 @default.
- W4387208907 hasConceptScore W4387208907C2780739268 @default.
- W4387208907 hasConceptScore W4387208907C509974204 @default.
- W4387208907 hasConceptScore W4387208907C71924100 @default.
- W4387208907 hasIssue "2" @default.
- W4387208907 hasLocation W43872089071 @default.
- W4387208907 hasLocation W43872089072 @default.
- W4387208907 hasOpenAccess W4387208907 @default.
- W4387208907 hasPrimaryLocation W43872089071 @default.
- W4387208907 hasRelatedWork W152659163 @default.
- W4387208907 hasRelatedWork W2154169709 @default.
- W4387208907 hasRelatedWork W2265981062 @default.
- W4387208907 hasRelatedWork W2411583971 @default.
- W4387208907 hasRelatedWork W2781286807 @default.
- W4387208907 hasRelatedWork W2806991430 @default.
- W4387208907 hasRelatedWork W31297289 @default.
- W4387208907 hasRelatedWork W4250397071 @default.
- W4387208907 hasRelatedWork W4378648248 @default.
- W4387208907 hasRelatedWork W3082504439 @default.
- W4387208907 hasVolume "117" @default.
- W4387208907 isParatext "false" @default.
- W4387208907 isRetracted "false" @default.
- W4387208907 workType "article" @default.